EncorePharma has its roots in an academic laboratory at Loma Linda University (LLU) and the pharmaceutical industry, where a previously close-knit group of researchers had assembled for an “Encore” performance in their professional lives. Under the direction of Dr. William J. Wechter, these researchers initially focused on the development of new clinical applications for what were considered to be “old” drugs, providing these medications with the opportunity for an “Encore” performance as well.

After a 10-year period of maturation at LLU, Encore Pharmaceuticals, Inc. (EncorePharma) concluded a technology transfer license agreement with Loma Linda University and was fully incorporated (Delaware Corporation) on May 29, 1997. EncorePharma’s founders, Dr. William J. Wechter and Dr. Robert Bratzler, subsequently recruited Dr. Barbara Loughman to head clinical development and regulatory affairs.

In its corporate infancy, EncorePharma focused on the development of its lead patented product, E-7869, the “pure” R-enantiomer form of flurbiprofen. E-7869 emerged from the family of nonsteroidal anti-inflammatory drugs (NSAIDs) where its known functions and newly discovered activities suggested the potential for anti-cancer and anti-Alzheimer’s activity. After a two year period of expedited clinical development, EncorePharma licensed E-7869 (now MPC-7869 also known as FLURIZAN™) TO Myriad Genetics, who will continue clinical trial development of the product. Clearly, this rapid licensing of E-7869 represented a major organizational and business achievement for the young EncorePharma Corporation.

In addition to E-7869, EncorePharma’s earliest efforts targeted the pharmacological activity of γ-tocopherol* (one component of the Vitamin E complex) and its derivatives, with special attention to the potential anti-cancer, anti-hypertensive and anti-oxidant properties of these compounds. Currently, the derivative of greatest interest is LLU-α – (also known as γ-CEHC, a natriuretic agent (chemical that elicits excretion of sodium). LLU-α was isolated and characterized by Dr. Wechter’s research group in the laboratories at Loma Linda University (LLU)

Through the development of its intellectual property, EncorePharma has broadened its in-house R&D operations to include research collaborations with several important academic and industrial organizations worldwide in a number of therapeutic areas.

*Patent-protected compounds or uses